• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Tandem Diabetes Care Appoints Raj Sodhi to Board of Directors

    12/14/20 4:05:00 PM ET
    $TNDM
    $RMD
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $TNDM alert in real time by email

    SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Rajwant (Raj) Singh Sodhi as an independent member of its board of directors effective January 1, 2021. He will succeed Edward Cahill, who has served as a board member for the Company since May 2009. Mr. Sodhi is president of the software as a service (SaaS) business at ResMed (NYSE: RMD, ASX: RMD). He brings to the Tandem board more than 25 years of digital strategy experience, SaaS commercialization and operations across multiple industries including healthcare, financial services, and telecom.

    “We are pleased to welcome Raj to our Board of Directors at this important next stage of Tandem’s evolution,” said John Sheridan, president and chief executive officer. “Raj’s deep experience in driving innovation through software technologies will be invaluable to Tandem as we grow our business and advance our ecosystem of data-driven products and services in support of improving the lives of people with diabetes.”

    “I’d like to express our deep appreciation to Ed for his contributions as a member of our Board over the past 11 years,” said Kim Blickenstaff, chairman of the board. “He has provided valuable insight and support at every stage of our company as we transformed from a small start-up to a leader in insulin therapy management.”

    Mr. Sodhi joined ResMed in 2012 through the acquisition of Umbian Inc., of which he was co-founder and president. Since that time, Mr. Sodhi has served in several positions at ResMed including President of Healthcare Informatics where he led the creation of ResMed’s portfolio of digital solutions that connects more than 12 million patients globally to ResMed’s ecosystem of cloud-connected medical devices and digital health technologies that have transformed care for people with sleep apnea, COPD, and other chronic diseases. Since 2016, Mr. Sodhi has led a series of healthcare IT acquisitions focused on software platforms serving providers outside of the hospital and building a new segment of growth for ResMed that represents 12 percent of ResMed’s global revenues and enables providers across the United States to serve more than 100M+ patients and residents.

    Before ResMed and Umbian, Mr. Sodhi worked in the financial services industry, designing, developing and managing SaaS solutions. He was senior vice president of business development and chief technology officer for Skipjack Financial Services, and co-founder and chief technology officer of TransActive Ecommerce Solutions. Mr. Sodhi holds a Master of Business Administration and a Bachelor of Science in mathematics and statistics from Dalhousie University in Halifax, Nova Scotia.

    About Tandem Diabetes Care, Inc.

    Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem’s flagship product, the t:slim X2™ insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring. Tandem is based in San Diego, California.

    Tandem Diabetes Care is a registered trademark and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.

    Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2, and $TNDM.
    Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
    Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.

    Get the next $TNDM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TNDM
    $RMD

    CompanyDatePrice TargetRatingAnalyst
    ResMed Inc.
    $RMD
    7/16/2026$234.00Outperform → Sector Perform
    RBC Capital Mkts
    ResMed Inc.
    $RMD
    7/13/2026$235.00Buy → Neutral
    Citigroup
    Tandem Diabetes Care Inc.
    $TNDM
    6/23/2026$15.50Hold
    Deutsche Bank
    ResMed Inc.
    $RMD
    6/17/2026$230.00Overweight → Equal-Weight
    Morgan Stanley
    Tandem Diabetes Care Inc.
    $TNDM
    6/1/2026$27.00Equal Weight → Overweight
    Wells Fargo
    Tandem Diabetes Care Inc.
    $TNDM
    5/12/2026Hold
    The Benchmark Company
    ResMed Inc.
    $RMD
    4/15/2026Overweight
    Analyst
    Tandem Diabetes Care Inc.
    $TNDM
    3/19/2026$35.00Hold → Buy
    Truist
    More analyst ratings

    $TNDM
    $RMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 28, 2025 - FDA Roundup: February 28, 2025

    For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy

    2/28/25 5:00:47 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    November 7, 2023 - FDA Roundup: November 7, 2023

    For Immediate Release: November 07, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA issued a Safety Communication warning consumers, health care providers, and health care facilities not to use recalled saline (0.9% sodium chloride) and sterile water medical products manufactured by Nurse Assist, LLC. On November 6, Nurse

    11/7/23 3:38:18 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    $RMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ResMed downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded ResMed from Outperform to Sector Perform and set a new price target of $234.00

    7/16/26 8:47:08 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    ResMed downgraded by Citigroup with a new price target

    Citigroup downgraded ResMed from Buy to Neutral and set a new price target of $235.00

    7/13/26 9:02:22 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Deutsche Bank initiated coverage on Tandem Diabetes Care with a new price target

    Deutsche Bank initiated coverage of Tandem Diabetes Care with a rating of Hold and set a new price target of $15.50

    6/23/26 7:56:39 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    $RMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD)

    TROY, Mich., July 21, 2026 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Broadridge Financial Resources Inc.(NYSE:BR) as its "Stock to Study" and ResMed Inc. (NYSE:RMD) as its "Undervalued Stock" in the October 2026 issue for investors' informational and educational use. To help you along your way, BetterInvesting has a number of free resources including: https://www.betterinvesting.org/learn-about-investing/investor-education/college-saving/investment-strategies-in-saving-for-collegeFor a free lesson on 6 steps to successful investing, visit https://www.betterinvesting.org/learn-about-investing/investor-education/getting-s

    7/21/26 4:40:00 PM ET
    $BR
    $RMD
    Real Estate
    Medical/Dental Instruments
    Health Care

    Resmed Announces Agreement to Sell MatrixCare Business

    SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners, a private equity firm focused exclusively on health care. This move reflects Resmed’s 2030 strategy by focusing on high-growth, scalable opportunities in sleep health, breathing health and connected home-based healthcare. The divestiture also strengthens Resmed’s ability to reallocate capital and resources toward innovation, operational scale and long-term value creation across its connected, home-

    7/7/26 4:30:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets

    Compatibility now available in five countries, with additional markets expected throughout 2026.Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced that the t:slim X2™ insulin pump with Control-IQ+TM automated insulin delivery (AID) technology is now compatible with Abbott’s FreeStyle Libre® 3 Plus continuous glucose monitoring (CGM) sensor in five countries. This launch expands continuous glucose monitoring choice for t:slim X2 pump users in the United Kingdom, Switzerland, Sweden, Finland, and Italy. Tandem expects to add additional countries in 2026, including Belgium, the Netherlands, and Germany."People using AID want fle

    7/1/26 8:30:00 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    $RMD
    SEC Filings

    View All

    ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - RESMED INC (0000943819) (Filer)

    7/7/26 5:24:32 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by ResMed Inc.

    144 - RESMED INC (0000943819) (Subject)

    7/7/26 10:07:44 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by Tandem Diabetes Care Inc.

    SD - TANDEM DIABETES CARE INC (0001438133) (Filer)

    5/28/26 4:53:55 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    $RMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CEO Sheridan John F bought $102,318 worth of shares (10,000 units at $10.23), increasing direct ownership by 10% to 106,327 units (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    8/11/25 6:15:44 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    EVP & CHIEF FINANCIAL OFFICER Vosseller Leigh bought $149,404 worth of shares (13,720 units at $10.89) (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    8/11/25 5:18:51 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    EVP & Chief Operating Officer Kyrillos Jean-Claude bought $190,966 worth of shares (10,538 units at $18.12) (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    3/11/25 6:06:01 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    $RMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Chief Operating Officer Kyrillos Jean-Claude converted options into 3,636 shares and covered exercise/tax liability with 1,926 shares, increasing direct ownership by 6% to 29,815 units (SEC Form 4) (tax withholding)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    7/17/26 4:07:23 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,090,771 worth of ResMed Common Stock (4,991 units at $218.55) as part of a pre-agreed trading plan (SEC Form 4)

    4 - RESMED INC (0000943819) (Issuer)

    7/9/26 7:40:12 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $968,064 worth of ResMed Common Stock (4,991 units at $193.96) as part of a pre-agreed trading plan, increasing direct ownership by 0.01% to 466,256 units (SEC Form 4)

    4 - RESMED INC (0000943819) (Issuer)

    6/9/26 2:26:30 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $TNDM
    $RMD
    Leadership Updates

    Live Leadership Updates

    View All

    Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor

    SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett Sandercock, Chief Financial Officer, plans to retire effective May 4, 2026. After conducting a comprehensive search, Aaron Bloomer has been appointed as his successor.  "After 27 years with Resmed, including 20 as CFO, Brett leaves an outstanding legacy of disciplined leadership and trusted partnership," said Mick Farrell, Chairman and CEO of Resmed. "Brett's leadership has helped guide Resmed through significant growth and transformation, while keeping a clear focus on long-term value creat

    4/30/26 4:10:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care Announces Appointment of Sandra Beaver to Board of Directors

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Sandra Beaver to its board of directors effective November 7, 2025. Ms. Beaver joins the board as an independent director and will serve on the board's Audit Committee and Cybersecurity and Data Oversight Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112460451/en/Sandra Beaver joins Tandem Diabetes Care Board of Directors. "We welcome Sandra to our Board of Directors at this pivotal stage in Tandem's evolution," said John Sheridan, president and CEO. "Sandra is a dynamic finance

    11/12/25 9:00:00 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Resmed Names Salli Schwartz as Chief Investor Relations Officer

    SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD), ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO. Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she

    4/21/25 5:00:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $TNDM
    $RMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tandem Diabetes Care Inc.

    SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

    11/14/24 4:15:44 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tandem Diabetes Care Inc.

    SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

    9/9/24 10:40:31 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Tandem Diabetes Care Inc.

    SC 13G - TANDEM DIABETES CARE INC (0001438133) (Subject)

    2/14/24 7:37:31 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    $RMD
    Financials

    Live finance-specific insights

    View All

    Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026

    SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2026 on Thursday, August 6, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Location:         https://investor.resmed.comDate:               Thursday, August 6, 2026Time:               1:30 p.m. PT / 4:30 p.m. ETInternational:   London, Thursday, August 6, 2026, 9:30 p.m. BST                        Sydney, Friday

    6/30/26 4:30:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care to Announce Second Quarter 2026 Financial Results on August 6, 2026

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2026 results after the financial markets close on Thursday, August 6, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2026 financial and operating results.A live webcast of the call will be available on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI09573d6

    6/30/26 8:30:00 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

    Noctrix Health acquisition validates Angelini Ventures' strategy of investing in innovative healthcare companies addressing significant unmet medical needs and advancing connected health Rome, Italy, 3rd June 2026 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and HealthTech, announces that portfolio company Noctrix Health has been acquired by ResMed (NYSE:RMD), a global leader in sleep health and respiratory care, in a transaction valued at $340 million. The transaction further strengthens Angelini Ventures' mission to support the next generation of healthcare innovators, combining capit

    6/3/26 7:40:36 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care